Leukaemia Section
Short Communication

t(3;6)(q25;q26)
Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Published in Atlas Database: May 2007
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0306q25q26ID1211.html
DOI: 10.4267/2042/38479
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

**Disease**
Acute myeloid leukaemia (AML) and treatment related acute myeloid leukaemia (t-AML).

**Epidemiology**
Only 2 cases to date, a 41 year old female patient with M1 AML, and a 70 year old male patient with t-AML.

**Prognosis**
No data.

Cytogenetics

**Cytogenetics, morphological**
Sole anomaly in the t-AML case, accompanied with del(7q) and a complex karyotype in the other case.

**Genes involved and Proteins**

**Note:** The partner of EVI1 is yet unknown.

**EVI1**
Location: 3q26.2

**Protein**
Transcription factor; EVI1 targets include: GATA2, ZBTB16 /PLZF, ZFPM2/FOG2, JNK and the PI3K/AKT pathway. Role in cell cycle progression, likely to be cell-type dependant; antiapoptotic factor; involved in neuronal development organogenesis; role in hematopoietic differentiation.

References


This article should be referenced as such: